{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Alpa Laboratories Ltd
Why is Alpa Laboratorie falling/rising?
On 02-Dec, Alpa Laboratories Ltd witnessed a significant price rise of 11.34%, closing at ₹86.47, marking a notable reversal after two days of decline and outperforming its sector by 11.33%.
Alpa Laboratories Stock Falls to 52-Week Low of Rs.76.25
Alpa Laboratories has reached a new 52-week low, with its share price touching Rs.76.25 today. This marks a significant level for the pharmaceutical and biotechnology company amid a broader market environment where the Sensex is trading slightly lower.
Alpa Laboratories Stock Falls to 52-Week Low of Rs.78.01
Alpa Laboratories has reached a new 52-week low of Rs.78.01, marking a significant decline amid broader market gains. The stock has underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.
Alpa Laboratories Falls to 52-Week Low of Rs.78.02 Amidst Market Rally
Alpa Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.78.02 today, marking a significant decline amid a broadly positive market environment where the Sensex advanced by 0.64%.
Alpa Laboratories Faces Financial Challenges Amidst Strong Sales Growth and Market Struggles
Alpa Laboratories has reported a challenging financial period for the quarter ending September 2025, with a decline in overall performance metrics. Despite a 21.86% increase in net sales to Rs 85.29 crore, profit after tax fell significantly. The company faces concerns regarding key performance indicators and market performance relative to the Sensex.
Alpa Laboratories Q2 FY26: Profit Plunges 98.57% as Operating Margins Turn Negative
Alpa Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported deeply troubling results for Q2 FY26, with consolidated net profit collapsing 98.57% year-on-year to just ₹0.11 crores from ₹7.69 crores in the same quarter last year. The catastrophic decline reflects severe operational distress as the company's operating margins turned sharply negative for the first time in recent years, raising serious questions about business viability. The stock, currently trading at ₹80.85 with a market capitalisation of ₹168.00 crores, has declined 28.70% over the past year, significantly underperforming both the benchmark Sensex and the pharmaceuticals sector.
Is Alpa Laboratorie overvalued or undervalued?
As of November 17, 2025, Alpa Laboratorie is considered overvalued and risky, with a PE Ratio of 9.02 and significant underperformance compared to peers like Sun Pharma and Cipla, as well as a year-to-date return of -33.37% against the Sensex's 8.72%.
How has been the historical performance of Alpa Laboratorie?
Alpa Laboratorie has shown steady growth in net sales and profit from Mar'20 to Mar'25, with net sales increasing from 85.97 Cr to 112.45 Cr, and profit before tax rising from 2.54 Cr to 25.67 Cr. Despite fluctuations in operating profit margins and rising raw material costs, the company's total assets and cash flow from operations have significantly improved.
Alpa Laboratories Stock Plummets to New 52-Week Low at Rs. 79.21
Alpa Laboratories has hit a new 52-week low of Rs. 79.21, reflecting a significant downturn after five days of gains. The stock has underperformed its sector and is trading below key moving averages. Over the past year, it has declined by 25.28%, contrasting with the Sensex's growth.
Alpa Laboratories Stock Plummets to New 52-Week Low at Rs. 79.21
Alpa Laboratories has hit a 52-week low of Rs. 79.21, following a five-day gain streak. The stock has underperformed its sector and is trading below all key moving averages. Despite modest growth in net sales and operating profit, its performance contrasts with broader market trends.
How has been the historical performance of Alpa Laboratorie?
Alpa Laboratorie has shown steady growth in net sales and profitability, with net sales increasing from 85.97 Cr in Mar'20 to 112.45 Cr in Mar'25, and profit after tax rising from 0.93 Cr to 19.50 Cr in the same period, indicating strong financial performance and operational efficiency. Total assets also grew significantly, reflecting robust asset accumulation.
Why is Alpa Laboratorie falling/rising?
As of 07-Nov, Alpa Laboratories Ltd's stock price is Rs. 81.83, down 6.67%, hitting a 52-week low of Rs. 79.8, and underperforming its sector. The stock has declined 10.55% over the past five days and is trading below all key moving averages, indicating a bearish trend with decreased investor participation.
Alpa Laboratories Stock Plummets to New 52-Week Low at Rs. 83.3
Alpa Laboratories has reached a 52-week low, reflecting ongoing challenges in the market. The microcap pharmaceutical company has seen a consistent decline over the past week and year, underperforming compared to sector peers. Despite a stable financial structure, growth and profitability remain difficult to achieve.
Why is Alpa Laboratorie falling/rising?
As of 17-Oct, Alpa Laboratories Ltd's stock price is Rs. 85.00, down 4.49%, marking a new 52-week low and underperforming its sector. The stock has declined 6.97% over the past week and 29.17% year-to-date, significantly lagging behind the benchmark Sensex.
Alpa Laboratories Hits 52-Week Low at Rs 91.00 Amid Market Volatility
Alpa Laboratories has reached a 52-week low, reflecting ongoing struggles despite a broader market recovery. The company has underperformed over the past year, with mixed financial metrics, including modest net sales growth and a low debt-to-equity ratio, indicating stability amid recent challenges.
Is Alpa Laboratorie overvalued or undervalued?
As of October 1, 2025, Alpa Laboratorie is considered very attractive due to its undervalued status with a PE ratio of 7.11, significantly lower than peers like Sun Pharma and Divi's Lab, and despite recent underperformance, it has shown strong long-term growth potential with a 196.66% gain over five years.
Is Alpa Laboratorie overvalued or undervalued?
As of October 1, 2025, Alpa Laboratorie is considered very attractive due to its undervaluation with a PE ratio of 7.11, a Price to Book Value of 1.09, and an EV to EBITDA of 15.80, significantly lower than peers like Sun Pharma and Divi's Lab, while also showing strong long-term growth potential despite recent stock performance declines.
Alpa Laboratories Stock Plummets to 52-Week Low at Rs 90
Alpa Laboratories has reached a 52-week low amid a broader market downturn, with its stock declining consecutively over three days. The company has faced challenges, reporting a one-year performance drop and limited growth in net sales, while trading below key moving averages in the Pharmaceuticals sector.
Why is Alpa Laboratorie falling/rising?
As of 24-Sep, Alpa Laboratories Ltd's stock price is Rs 93.19, down 1.88%, and it is underperforming its sector and the Sensex. The stock is in a bearish trend, trading below all key moving averages, with a significant drop in investor participation and a year-to-date decline of 22.34%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
